Logo

Meiji and Dong-A ST Sign an Exclusive License Agreement with Intas to Commercialize DMB-3115- Proposed Biosimilar to Ustekinumab

Share this

Meiji and Dong-A ST Sign an Exclusive License Agreement with Intas to Commercialize DMB-3115- Proposed Biosimilar to Ustekinumab

Shots:

  • Meiji and Dong-A ST to receive an upfront & will be eligible to receive development & sales milestones along with profit share. The companies collaborated to commercialize DMB-3115 proposed biosimilar to ustekinumab for the treatment of inflammatory diseases such as PsO- CD & UC
  • Intas to get exclusive license rights to commercialize DMB-3115 globally- Ex-Japan- Korea & Asia. Meiji and Dong-A ST will develop and manufacture DMB-3115 and supply the product to Intas and its WW affiliates
  • DMB-3115 is being evaluated in a P-III multi-regional clinical trial to treat patients with PsO in the EU & US

  | Ref: Meiji | Image: Meiji

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions